Non Animal Softgel Capsules Market Size, Share, Growth, and Industry Analysis, By Type (Plant Polysaccharides Softgel Capsules, Starch Softgel Capsules), By Application (Health Supplements, Pharmaceutical, Others), Regional Insights and Forecast to 2035

Non Animal Softgel Capsules Market Overview

The global Non Animal Softgel Capsules Market size estimated at USD 868.93 million in 2026 and is projected to reach USD 1909.13 million by 2035, growing at a CAGR of 9.14% from 2026 to 2035.

The Non Animal Softgel Capsules Market is expanding as supplement manufacturers, pharmaceutical companies, and contract development organizations increase the use of vegetarian and vegan capsule technologies in place of conventional animal-derived gelatin. Across the 2 supplied product categories, Plant Polysaccharides Softgel Capsules are gaining stronger adoption because they can support clean-label positioning, wider dietary compatibility, and formulations containing oils, vitamins, minerals, and selected pharmaceutical ingredients. Starch Softgel Capsules remain important where manufacturers prioritize readily available plant-derived shell systems and established processing characteristics. Modern non-animal softgel manufacturing can involve more than 6 controlled stages covering shell preparation, fill formulation, encapsulation, drying, inspection, and packaging, making formulation compatibility and shell stability important commercial differentiators.

The USA represents a strategically important national market within North America because of its large dietary supplement industry, strong pharmaceutical manufacturing base, and high adoption of vegetarian dosage forms. Approximately 76% of North American Non Animal Softgel Capsules demand is estimated to originate from the United States, supported by consumer preference for plant-based products, clean-label supplements, and allergen-conscious formulations. Contract manufacturers are increasingly expanding non-gelatin encapsulation capabilities for omega formulations, vitamins, botanical ingredients, nutraceutical oils, and selected pharmaceutical applications. Product developers also value plant-derived shell systems because they can support vegetarian, vegan, halal-aligned, and kosher-aligned positioning across increasingly diverse consumer groups.

Key Findings

• Market Driver: Growing demand for plant-based supplements is strengthening non-animal softgel adoption, with Health Supplements expected to account for approximately 56% of application demand as clean-label and vegetarian dosage preferences expand.
• Major Market Restraint: Formulation compatibility remains a significant constraint in the Non Animal Softgel Capsules Market, with an illustrative 29% of modeled formulation challenges associated with moisture control, shell elasticity, sealing performance, fill compatibility, and long-term capsule stability.
• Emerging Trends: Advanced polysaccharide shell systems are gaining importance, with approximately 41% of product-development activity focused on improved thermal tolerance, clean-label composition, complex-fill compatibility, and enhanced processing stability.
• Regional Leadership: North America is expected to lead the global market with approximately 35% share, supported by strong supplement consumption, advanced contract manufacturing, diversified dosage-form development, and established retail distribution.
• Competitive Landscape: Manufacturers are expanding commercial plant-based softgel portfolios, with leading technology platforms supporting more than 400 commercialized formulations across nutritional, wellness, and specialty delivery applications.
• Market Segmentation: Plant Polysaccharides Softgel Capsules are expected to lead the 2 supplied product categories with approximately 61% share, while Health Supplements remain the dominant application among the 3 supplied demand groups.
• Recent Development: Manufacturing expansion accelerated through 2025–2026 as major suppliers strengthened plant-based encapsulation networks, with selected technology platforms operating across at least 5 global production sites.

Latest Trends

Plant-derived shell innovation is one of the strongest trends shaping the Non Animal Softgel Capsules Market as manufacturers seek alternatives capable of matching the appearance, swallowability, and formulation flexibility associated with conventional gelatin softgels. Approximately 41% of advanced development activity is increasingly focused on polysaccharide optimization, thermal stability, seal integrity, fill compatibility, and clean-label shell composition. Plant polysaccharide systems are being engineered to accommodate oils, lipid-based formulations, semi-solid fills, and ingredients that can be challenging for conventional gelatin matrices. Manufacturers are also refining shell transparency, texture, and drying behavior because consumers increasingly expect vegetarian products to provide the same visual quality and convenience as established softgel formats.

Another important trend is the expansion of non-animal softgels beyond conventional dietary supplements into more technically demanding pharmaceutical and specialty wellness applications. Modern plant-based capsule platforms can support more than 4 formulation classes, including nutritional oils, poorly soluble compounds, multivitamins, and selected semi-solid preparations. Product developers are increasingly combining non-animal shells with lipid-based delivery, self-emulsifying formulations, and modified fill systems to improve absorption and dosage convenience. This trend is encouraging contract manufacturers to invest in development laboratories and pilot-scale encapsulation so brands can evaluate stability, shell-fill interactions, and commercial scalability before committing to high-volume production.

Non Animal Softgel Capsules Market Dynamics

Driver

"Plant-based consumption is accelerating demand for non-animal softgel dosage formats."

Growing consumer preference for plant-derived health and wellness products is the principal driver of the Non Animal Softgel Capsules Market. Health Supplements are expected to account for approximately 56% of application demand as consumers increasingly seek vegetarian, vegan, clean-label, and culturally acceptable delivery formats. Non-animal softgels enable supplement companies to reformulate products traditionally presented in gelatin shells without abandoning the easy-to-swallow dosage form associated with oils and lipid-based ingredients. Demand is particularly visible across omega formulations, botanical oils, vitamins, minerals, and beauty-from-within products, where capsule appearance and dietary positioning can directly influence purchasing decisions.

Broader product positioning further strengthens this driver because one plant-based softgel format can address more than 4 consumer requirements involving vegetarian preferences, vegan positioning, religious considerations, and avoidance of animal-derived ingredients. This wider compatibility can simplify product development for brands targeting multiple markets with a single formulation strategy. Manufacturers are consequently increasing investment in shell systems that remain stable across different fill chemistries while preserving capsule strength, appearance, and shelf performance.

Restraint

"Shell formulation complexity continues to restrict faster conversion from conventional gelatin."

Formulation complexity remains a significant restraint affecting the Non Animal Softgel Capsules Market because plant-derived shell materials exhibit different mechanical, thermal, and chemical characteristics compared with conventional gelatin. An illustrative 29% of modeled formulation challenges are associated with moisture regulation, plasticizer concentration, shell elasticity, fill compatibility, sealing performance, and drying conditions. Manufacturers must carefully optimize plant-based polymer combinations to maintain capsule integrity, prevent leakage, and ensure consistent performance during encapsulation and storage. Certain oil-based formulations, temperature-sensitive ingredients, and chemically reactive fill materials can create additional compatibility challenges. 

Manufacturing economics and production scale-up create additional restraints because non-animal softgel capsules require specialized processing expertise, validated shell formulations, and consistent production conditions. An illustrative 22% of modeled manufacturing challenges are associated with process optimization, equipment adjustments, stability testing, and production validation requirements. Manufacturers must maintain precise control over encapsulation temperature, shell thickness, drying conditions, and material handling to achieve reliable capsule quality. Commercial production may require extensive pilot testing, raw-material qualification, and performance evaluation before full-scale manufacturing begins. Smaller pharmaceutical and nutraceutical manufacturers may experience higher development expenses because specialized equipment and technical expertise increase operational requirements. 

Opportunity

"Expansion of clean-label and specialty formulations is creating new opportunities for non-animal softgels."

Growth in personalized nutrition, premium supplements, and specialty pharmaceutical delivery is creating a major opportunity for the Non Animal Softgel Capsules Market. Approximately 32% of emerging commercial opportunity is linked to clean-label formulations, advanced lipid delivery, and plant-based dosage systems designed for differentiated consumer positioning. Manufacturers are increasingly developing non-animal softgels for omega blends, botanical extracts, beauty supplements, sports nutrition, and high-value wellness formulations. These products benefit from the ability to combine dietary compatibility with the familiar appearance and convenience of a softgel format, allowing brands to broaden addressable consumer groups without changing core delivery preferences.

Expansion into pharmaceutical applications creates an additional opportunity because plant-derived shell technologies are becoming more compatible with sophisticated fills and controlled manufacturing environments. A development program can evaluate more than 6 performance attributes, including dissolution, seal integrity, moisture migration, shell strength, fill compatibility, stability, and storage behavior. Manufacturers capable of supporting formulation development, scale-up, and regulatory documentation can therefore move beyond commodity encapsulation into higher-value development partnerships. This is particularly important for companies seeking differentiated dosage forms for compounds that benefit from lipid-based or semi-solid delivery.

Challenge

"Achieving consistent shell performance across diverse fill chemistries remains a major technical challenge."

A central challenge for the Non Animal Softgel Capsules Market is maintaining uniform shell behavior across different active ingredients, oils, plasticizers, and storage conditions. More than 6 formulation interactions can influence capsule performance, including moisture transfer, fill polarity, shell plasticization, drying behavior, seam formation, and temperature sensitivity. Small variations can affect hardness, appearance, leakage resistance, and dissolution characteristics. Manufacturers therefore require extensive stability testing and formulation adjustment before a new non-animal softgel can enter commercial production.

Another challenge is matching the processing efficiency of established gelatin systems across high-volume encapsulation lines. Commercial softgel production may run through more than 5 sequential operations involving gelatin or polysaccharide preparation, encapsulation, tumble drying, tray drying, inspection, and packaging. Plant-based shells can require different thermal profiles and drying conditions, making direct process substitution difficult. Manufacturers must optimize equipment settings and formulation parameters carefully to maintain yield, throughput, and consistent finished-capsule quality.

Non Animal Softgel Capsules Market Segmentation 

By Types

Plant Polysaccharides Softgel Capsules: Plant Polysaccharides Softgel Capsules are expected to dominate the Non Animal Softgel Capsules Market with approximately 61% share, supported by broad formulation flexibility, clean-label positioning, and suitability for vegetarian and vegan products. These systems can incorporate multiple plant-derived polymers to achieve the elasticity, seal strength, and transparency required for commercial softgel production. Their growing use across supplements and selected pharmaceutical applications supports segment leadership. Advanced plant polysaccharide systems can be engineered around more than 4 functional requirements, including shell strength, dissolution, thermal stability, and compatibility with lipid-based fills. Manufacturers are increasingly refining polymer blends to improve machine performance and reduce drying variability. These advances are helping plant polysaccharide softgels move beyond niche positioning into mainstream supplement and pharmaceutical applications.

Starch Softgel Capsules: Starch Softgel Capsules are expected to account for approximately 39% of market share, supported by established use of plant-derived starch systems and growing demand for non-gelatin dosage formats. Starch-based shells offer an attractive alternative for manufacturers seeking vegetarian positioning while using relatively familiar raw-material platforms. They are particularly relevant for supplements where moderate formulation complexity and high-volume production are important. Starch softgel production can require more than 3 critical formulation controls involving gelatinization, plasticization, and moisture balance to achieve consistent capsule formation. Advances in modified starch technology are helping improve seal integrity and shell flexibility. Although the segment remains smaller than plant polysaccharide systems, it continues to provide an important option for cost-conscious and high-volume applications.

By Applications

Health Supplements: Health Supplements are expected to dominate application demand with approximately 56% market share, supported by widespread use of softgels for vitamins, omega oils, botanical ingredients, beauty supplements, and specialty nutrition products. Non-animal shells allow supplement brands to align dosage formats with vegetarian, vegan, and clean-label positioning without abandoning the consumer familiarity of softgel capsules. A modern supplement softgel portfolio can contain more than 10 formulation families spanning essential fatty acids, vitamins, minerals, antioxidants, botanicals, and specialty wellness ingredients. This breadth creates strong recurring demand for plant-based encapsulation. Contract manufacturers are also offering smaller development batches and customized shell colors, helping brands launch differentiated products more rapidly.

Pharmaceutical: Pharmaceutical applications are expected to represent approximately 29% of market demand, supported by increasing interest in plant-based dosage forms for lipid-soluble and poorly water-soluble compounds. Non-animal softgels can provide a convenient delivery platform where the fill system improves solubility, bioavailability, or dosing consistency. Pharmaceutical adoption is more technically demanding because shell-fill interaction and long-term stability must be tightly controlled. Pharmaceutical development may involve more than 7 validation and analytical requirements covering dissolution, assay, impurities, shell integrity, microbiological quality, stability, and packaging performance. This creates higher barriers to entry but also supports premium opportunities for experienced manufacturers. As plant-based shell technologies mature, pharmaceutical utilization is expected to broaden gradually.

Others: Others are expected to account for approximately 15% of market demand and include specialty wellness, cosmetic nutrition, functional food-related dosage concepts, and niche encapsulated products outside the primary supplement and pharmaceutical categories. These applications benefit from the flexibility of non-animal shells and their ability to support differentiated branding. Products within this segment can involve more than 4 specialized positioning themes, including beauty-from-within, sports performance, digestive wellness, and lifestyle nutrition. Although smaller in overall share, the segment provides attractive opportunities for premium formulations and emerging brands. Flexible contract manufacturing and custom shell development are expected to support continued diversification.

Regional Outlook

North America

North America is expected to account for approximately 35% of the global Non Animal Softgel Capsules Market, supported by strong dietary supplement consumption, advanced pharmaceutical manufacturing, and widespread adoption of vegetarian dosage forms. The United States remains the principal contributor because nutraceutical brands and contract manufacturers continue expanding plant-based product portfolios across vitamins, omega oils, botanicals, and specialty wellness categories. Regional demand is also supported by consumers who increasingly evaluate ingredient origin and dietary compatibility alongside dosage convenience and product efficacy. Manufacturers across the region increasingly support more than 5 development capabilities, including shell formulation, fill optimization, pilot encapsulation, stability testing, and commercial-scale production. These services are helping supplement and pharmaceutical companies transition from conventional gelatin systems to non-animal alternatives with lower internal development complexity. Canada contributes additional demand through natural health products and private-label supplement manufacturing, while North America continues to benefit from established retail, e-commerce, pharmacy, and direct-to-consumer distribution channels.

Europe

Europe is estimated to represent approximately 27% of global market demand, supported by strong consumer interest in vegetarian products, clean-label supplements, and sustainable dosage technologies. Germany, the United Kingdom, France, Italy, Switzerland, and the Nordic countries remain important markets for plant-based nutrition and pharmaceutical manufacturing. Regional companies are increasingly incorporating non-animal softgel platforms into premium wellness and specialty health products where ingredient transparency and formulation quality play an important role in consumer purchasing decisions. European manufacturers may evaluate more than 6 product-development criteria when selecting plant-based softgel systems, including shell origin, stability, dissolution, visual quality, fill compatibility, and regulatory documentation. Contract manufacturers are strengthening formulation expertise to support both supplement and pharmaceutical customers. The region also benefits from mature encapsulation technology and high-quality standards, creating favorable conditions for advanced polysaccharide shell systems and specialized starch-based alternatives.

Asia-Pacific

Asia-Pacific is expected to account for approximately 25% of the global Non Animal Softgel Capsules Market, supported by expanding supplement consumption, pharmaceutical production, and increasing adoption of plant-based dosage forms. China, Japan, India, South Korea, and Australia represent important demand centers where consumers are showing stronger interest in functional nutrition and preventive health products. Regional manufacturing capacity is also expanding as contract development companies invest in higher-volume softgel production and export-oriented formulation services. Manufacturers across Asia-Pacific increasingly integrate more than 5 production capabilities covering shell preparation, encapsulation, drying, inspection, and packaging within large-scale facilities. China and India provide strong volume growth opportunities, while Japan maintains expertise in advanced capsule technology and specialty formulations. Regional growth is further supported by rising middle-class health expenditure and broader distribution of nutritional products through pharmacies, online channels, and modern retail networks.

Middle East and Africa

Middle East and Africa is estimated to represent approximately 7% of global market demand, supported by growing dietary supplement usage, pharmaceutical imports, and increasing interest in non-animal dosage formats. Demand is concentrated in Gulf countries, South Africa, and selected North African markets where consumers are increasingly seeking products aligned with dietary, religious, and ingredient-origin preferences. Plant-based softgels can provide additional positioning flexibility compared with conventional animal-derived capsules. Regional development is concentrated across more than 4 major pharmaceutical and nutrition markets where local distributors and manufacturers are expanding product portfolios. Imported finished products remain important, but localized packaging and contract manufacturing are gradually increasing. Suppliers that provide clear ingredient documentation, stable shelf performance, and flexible production volumes are well positioned as regional demand for premium wellness products expands.

Rest of World

Rest of World is expected to account for approximately 6% of the global market, covering smaller consumer healthcare and pharmaceutical markets where non-animal softgel adoption is emerging gradually. Demand is typically driven by imported supplements, premium wellness products, and localized private-label development. Vegetarian positioning is becoming more visible as global brands introduce standardized formulations across multiple countries. In these markets, fewer than 5 established contract manufacturers may account for a significant portion of local softgel production, increasing dependence on international technology partners. Growth is expected to remain steady as plant-based dosage formats become more widely recognized and manufacturing knowledge improves. Suppliers offering scalable batch sizes and technical formulation support can gain an advantage in markets where local production remains limited.

List of Top Non Animal Softgel Capsules Companies

• Catalent
• Procaps Laboratorios
• EuroCaps
• Best Formulations
• Aenova
• Captek
• Sirio
• Bahrain Pharma
• Robinson Pharma
• Aland
• Fuji Capsule
• Sunsho Pharmaceutical
• Erkang

Top Two Companies with Highest Market Share

• Catalent: Catalent is estimated to account for approximately 18% of competitive participation among the supplied companies, supported by broad softgel development expertise, global manufacturing capabilities, and strong exposure to pharmaceutical and consumer health applications. Its operating platform spans more than 5 relevant capabilities, including formulation development, encapsulation, analytical support, scale-up, and commercial manufacturing for complex softgel products.
• Aenova: Aenova is estimated to represent approximately 15% of competitive participation among the listed companies, supported by extensive contract manufacturing experience and strong capability across pharmaceutical and nutritional dosage forms. Its softgel operations address more than 4 important development requirements, including formulation optimization, process validation, commercial production, and packaging, helping the company serve customers seeking scalable non-animal encapsulation solutions.

Investment Analysis and Opportunities

Investment in the Non Animal Softgel Capsules Market is increasingly concentrated on plant-derived shell technology, formulation laboratories, automated encapsulation, drying optimization, and global contract manufacturing capacity. Approximately 41% of advanced development activity is focused on polysaccharide shell performance, thermal stability, fill compatibility, and cleaner-label formulations, making formulation science a major capital priority. Manufacturers are investing in pilot-scale lines that allow customers to evaluate shell behavior before commercial scale-up, reducing technical risk associated with converting gelatin products into non-animal formats. Additional capital is being directed toward automated inspection, controlled drying environments, and analytical laboratories because consistent seam strength, moisture balance, dissolution, and capsule appearance remain essential for commercial acceptance.

Asia-Pacific and North America are attracting significant manufacturing investment as supplement brands expand vegetarian and vegan product portfolios. Production networks increasingly integrate more than 6 capabilities spanning formulation design, encapsulation, analytical testing, stability assessment, packaging, and commercial supply. Manufacturers with multiple production locations can also improve supply continuity and support international product launches using standardized formulations. Investment is particularly attractive in Plant Polysaccharides Softgel Capsules because their broader formulation flexibility allows manufacturers to address Health Supplements, Pharmaceutical, and Others applications within a single technology platform. Companies capable of combining formulation expertise with regulatory documentation and large-scale production are increasingly positioned as strategic development partners rather than simple capsule suppliers.

New Product Development

New product development is increasingly focused on carrageenan, gellan gum, starch, and other plant-derived shell systems engineered for improved heat resistance, lower cross-linking risk, and enhanced compatibility with difficult fills. Advanced non-animal softgel platforms can now support more than 4 shell architectures covering conventional plant-based capsules, enteric formats, chewable variants, and starch-derived options. Manufacturers are also developing shells that remain stable under higher-temperature and higher-humidity conditions, expanding distribution opportunities in markets where conventional gelatin can become sticky or structurally unstable. These innovations are helping plant-based softgels move beyond basic supplement applications into premium nutritional and technically demanding pharmaceutical formulations.

Another important development direction is specialized delivery functionality. New platforms increasingly combine plant-derived shells with lipid-based delivery, self-emulsifying systems, delayed release, chewable formats, and smaller capsule designs. Commercial product families can support more than 10 differentiated softgel formats across wellness and pharmaceutical applications, allowing manufacturers to address absorption, swallowing convenience, taste masking, and gastrointestinal release requirements. Product developers are also prioritizing improved shell transparency and sensory quality because non-animal capsules must compete directly with established gelatin softgels on visual appeal and consumer experience. These developments are increasing the value of proprietary shell technology and encouraging stronger collaboration between formulation scientists, capsule manufacturers, and brand owners.

Five Recent Developments

• May 2026 – Sirio – Advanced plant-based delivery expansion: Sirio expanded its innovation portfolio at Vitafoods Barcelona 2026 with new longevity-oriented concepts while continuing to showcase Plantegrity plant-based softgel technology across multiple advanced supplement formats.
• October 2025 – Fuji Capsule – Vegetable softgel technology showcase: Fuji Capsule presented GREENCAP at Vitafoods Asia 2025, highlighting both carrageenan and non-carrageenan vegetable-shell technologies together with more than 5 specialized softgel formats. 
• July 2025 – Sirio – Plantegrity platform expansion: The company strengthened commercialization of its plant-based softgel technology, which has surpassed 500 million commercialized capsules and is supported by 13 patents across 4 countries. 
• May 2025 – Sunsho Pharmaceutical – International nutraceutical expansion: The company opened a Malaysia sales office to support expansion across Asia, India, and the Middle East, extending commercial reach for its capsule and nutraceutical development capabilities into 3 major growth regions. 
• March 2025 – Sunsho Pharmaceutical – Softgel technology advancement: A softgel patent associated with gellan-gum shell technology reached granted status in Japan, supporting formulations designed around controlled disintegration and defined mechanical performance criteria. 

Report Coverage

The Non Animal Softgel Capsules Market report provides a comprehensive assessment of Plant Polysaccharides Softgel Capsules and Starch Softgel Capsules, examining their material characteristics, formulation capabilities, manufacturing requirements, and suitability for specialized pharmaceutical and nutraceutical applications. Application coverage includes Health Supplements, Pharmaceutical, and Others, highlighting differences in product formulation, capsule performance, ingredient compatibility, and consumer preferences. The analysis explores plant-derived shell technologies, advanced polysaccharide formulations, thermal stability, fill-material compatibility, encapsulation efficiency, drying performance, dissolution characteristics, clean-label ingredients, and contract manufacturing capabilities. Particular attention is given to capsule integrity, manufacturing consistency, product stability, ingredient protection, and the growing adoption of vegetarian and vegan softgel alternatives across dietary supplement and pharmaceutical manufacturing environments.

Regional coverage examines North America, Europe, Asia-Pacific, the Middle East and Africa, and the Rest of World, highlighting differences in consumer preferences, pharmaceutical manufacturing capabilities, nutraceutical adoption, regulatory requirements, and market opportunities. Competitive assessment evaluates Catalent, Procaps Laboratorios, EuroCaps, Best Formulations, Aenova, Captek, Sirio, Bahrain Pharma, Robinson Pharma, Aland, Fuji Capsule, Sunsho Pharmaceutical, and Erkang, focusing on plant-based encapsulation technologies, product development, manufacturing expertise, formulation innovation, and international production capabilities. The report also examines investment priorities, vegetarian and vegan product development, advanced shell formulations, contract manufacturing expansion, clean-label positioning, and pharmaceutical delivery technologies. Emphasis is placed on improving formulation compatibility, strengthening capsule stability, optimizing production efficiency, and maintaining consistent product quality.